Disease markers and uses thereof

摘要

A method of monitoring myositis disease progression of a patient receiving treatment with a therapeutic agent comprising (i) obtaining a first IFN±-inducible PD marker expression profile in a first sample from the patient; (ii) obtaining a second IFN±-inducible PD marker expression profile in a second sample from the patient after a therapeutic agent has been administered; and (iii) comparing the first and the second IFN±-inducible PD marker expression profiles, wherein the IFN±-inducible PD marker expression profile is based upon up-regulation of the expression of the following genes EPSTI1, HERC5, IFI27, IFI44, IFI44L, IFI6, IFIT1, IFIT3, ISG15, LAMP3, LY6E, MX1, OAS1, OAS2, OAS3, RSAD2, RTP4, SIGLEC1, and USP18; and wherein a variance in the first and the second IFN±-inducible PD marker expression profiles indicates a level of efficacy of the therapeutic agent, wherein the variance is a decrease in up-regulated expression of the gene.